-Decreased CSF P-tau levels-Better performance on the cognitive subscale of the Alzheimer’s Disease Assessment Scale and in attention tasks-Good overall tolerability (Forlenza et al., 2011). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.